FDA approves Roche's test to inform immunotherapy treatment decisions

Tucscon, Ariz.-based Ventana, a subsidiary of Roche, earned Food and Drug Administration approval for the Ventana PD-L1 Assay.

The assay functions as a diagnostic tool to identify PD-L1 levels in patients considering treatment with Roche's cancer drug Tecentriq. PD-L1 is a protein that makes individuals more receptive to immunotherapy treatments.

Better insight into a patient's PD-L1 levels can indicate the potential survival benefits associated with using Tecentriq as a treatment.

More articles on supply chain:

EpiPen price hikes cost DOD millions
Kits for care: How global sourcing helped Northside Hospital boost patient comfort
FDA approves Medtronic's larger aortic valve replacement system

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars